NASDAQ:CORTCorcept Therapeutics Stock Price, Forecast & News

Corcept Therapeutics' stock was trading at $10.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CORT shares have increased by 36.3% and is now trading at $14.92. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corcept Therapeutics.

Corcept Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Corcept Therapeutics.

Corcept Therapeutics Incorporated (NASDAQ:CORT) released its quarterly earnings results on Monday, May, 4th. The biotechnology company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $0.03. The biotechnology company had revenue of $93.25 million for the quarter, compared to analyst estimates of $87.01 million. Corcept Therapeutics had a return on equity of 30.00% and a net margin of 31.64%. The business's quarterly revenue was up 43.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 EPS. View Corcept Therapeutics' earnings history.

Corcept Therapeutics issued an update on its FY 2020 After-Hours earnings guidance on Monday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $355-375 million, compared to the consensus revenue estimate of $363.79 million.

3 brokerages have issued twelve-month price objectives for Corcept Therapeutics' stock. Their forecasts range from $15.00 to $20.00. On average, they expect Corcept Therapeutics' share price to reach $17.67 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price. View analysts' price targets for Corcept Therapeutics.

News headlines about CORT stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Corcept Therapeutics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutCorcept Therapeutics.

Corcept Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 21,980,000 shares, an increase of 5.5% from the April 15th total of 20,830,000 shares. Based on an average trading volume of 1,120,000 shares, the days-to-cover ratio is currently 19.6 days. Approximately 21.3% of the company's stock are sold short. View Corcept Therapeutics' Current Options Chain.

Some companies that are related to Corcept Therapeutics include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), CA (CA), Advanced Micro Devices (AMD), Alibaba Group (BABA), BlackRock (BLK), AbbVie (ABBV), Netflix (NFLX), Energy Transfer LP Unit (ET) and Johnson & Johnson (JNJ).

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Corcept Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (13.30%), Ingalls & Snyder LLC (6.98%), Federated Hermes Inc. (4.55%), State Street Corp (2.77%), Geode Capital Management LLC (1.29%) and Invesco Ltd. (1.19%). Company insiders that own Corcept Therapeutics stock include G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Robert S Fishman and Sean Maduck. View institutional ownership trends for Corcept Therapeutics.

CORT stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BlackRock Inc., Invesco Ltd., Morgan Stanley, Morgan Stanley, First Trust Advisors LP, Wellington Management Group LLP, and Engineers Gate Manager LP. View insider buying and selling activity for Corcept Therapeutics.

CORT stock was purchased by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Matarin Capital Management LLC, AJO LP, MERIAN GLOBAL INVESTORS UK Ltd, Oxford Financial Group Ltd., Aviva PLC, Schroder Investment Management Group, and Nuveen Asset Management LLC. View insider buying and selling activity for Corcept Therapeutics.

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CORT stock can currently be purchased for approximately $14.92.

Corcept Therapeutics has a market capitalization of $1.71 billion and generates $306.49 million in revenue each year. The biotechnology company earns $94.18 million in net income (profit) each year or $0.77 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.

The official website for Corcept Therapeutics is www.corcept.com.

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]